251 related articles for article (PubMed ID: 22920643)
1. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
Cockwell P; Cook M
Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
[TBL] [Abstract][Full Text] [Related]
4. Myeloma kidney: improving clinical outcomes?
Haynes R; Leung N; Kyle R; Winearls CG
Adv Chronic Kidney Dis; 2012 Sep; 19(5):342-51. PubMed ID: 22920645
[TBL] [Abstract][Full Text] [Related]
5. Management options for cast nephropathy in multiple myeloma.
Cockwell P; Hutchison CA
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
[TBL] [Abstract][Full Text] [Related]
6. High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.
Sinisalo M; Silvennoinen R; Wirta O
Am J Hematol; 2012 Jun; 87(6):640. PubMed ID: 22473521
[TBL] [Abstract][Full Text] [Related]
7. Optimizing treatment strategies in myeloma cast nephropathy: rationale for a randomized prospective trial.
Bridoux F; Fermand JP
Adv Chronic Kidney Dis; 2012 Sep; 19(5):333-41. PubMed ID: 22920644
[TBL] [Abstract][Full Text] [Related]
8. Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
Tan J; Lam-Po-Tang M; Hutchison CA; de Zoysa JR
Nephrology (Carlton); 2014 Jul; 19(7):432-5. PubMed ID: 24931113
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acute kidney injury with cast nephropathy.
Walther C; Podoll AS; Finkel KW
Clin Nephrol; 2014 Jul; 82(1):1-6. PubMed ID: 24725380
[TBL] [Abstract][Full Text] [Related]
10. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A
Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183
[TBL] [Abstract][Full Text] [Related]
11. Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
Martín-Gómez MA; García-Marcos SA; Caba-Molina M; Palacios-Gómez ME; Gómez-Morales M; Claver-Ferré C
Nefrologia; 2013 Nov; 33(6):862-4. PubMed ID: 24241381
[No Abstract] [Full Text] [Related]
12. Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study.
Peters NO; Laurain E; Cridlig J; Hulin C; Cao-Huu T; Frimat L
Hemodial Int; 2011 Oct; 15(4):538-45. PubMed ID: 22111823
[TBL] [Abstract][Full Text] [Related]
13. [Improved prognosis in light chain nephropathy due to multiple myeloma].
Juul JS; Larsen T; Marcussen N; Pedersen EB
Ugeskr Laeger; 2012 Apr; 174(17):1159-60. PubMed ID: 22533933
[TBL] [Abstract][Full Text] [Related]
14. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.
Fabbrini P; Finkel K; Gallieni M; Capasso G; Cavo M; Santoro A; Pasquali S
J Nephrol; 2016 Dec; 29(6):735-746. PubMed ID: 27757797
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal treatment of cast nephropathy.
Gakhar B; Kobrin S; Berns JS
Semin Dial; 2011; 24(1):9-11. PubMed ID: 21324000
[TBL] [Abstract][Full Text] [Related]
16. Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy.
Ward F; Dunne O; Crotty TB; Fennelly D; Watson A; Holian J
Ir Med J; 2012 May; 105(5):148-9. PubMed ID: 22803494
[TBL] [Abstract][Full Text] [Related]
17. Lambda light chain myeloma with oliguric cast nephropathy and remission with bortezomib, doxorubicin and dexamethasone.
Hada R; Poudyal B; Sharma A; Khatri R
JNMA J Nepal Med Assoc; 2012; 52(188):192-5. PubMed ID: 23591252
[TBL] [Abstract][Full Text] [Related]
18. Cast nephropathy with acute renal failure treated with high cut-off haemodialysis in a patient with multiple myeloma.
Shum HP; Chan KC; Chow CC; Kho BC; Yan WW
Hong Kong Med J; 2010 Dec; 16(6):489-92. PubMed ID: 21135429
[TBL] [Abstract][Full Text] [Related]
19. Extended high cutoff on-line hemodiafiltration is superior to extended high cutoff hemodialysis in removal of free light chain immunoglobulin of myeloma cast nephropathy.
Susantitaphong P; Tiranathanagul K; Eiam-Ong S
Artif Organs; 2012 Sep; 36(9):845-6. PubMed ID: 22497276
[No Abstract] [Full Text] [Related]
20. Renal improvement in myeloma with plasma exchange.
Hutchison C; Bridoux F; Fermand JP
N Engl J Med; 2011 Sep; 365(11):1061; author reply 1062. PubMed ID: 21916654
[No Abstract] [Full Text] [Related]
[Next] [New Search]
